Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life - Université de Rennes Access content directly
Journal Articles Clinical and experimental rheumatology Year : 2016

Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life

Chahéra Khouatra
  • Function : Author
Pierre Gobert
  • Function : Author
Claire Blanchard-Delaunay
  • Function : Author
Pascal Godmer
  • Function : Author
Pierre-Louis Carron
  • Function : Author
Nicolas Limal
  • Function : Author
Maïzé Ducret
  • Function : Author
Bernard Bonnotte
Alfred Mahr
  • Function : Author

Abstract

OBJECTIVES: To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy. METHODS: In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed. RESULTS: Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demonstrated by SF-36, study patients' baseline HRQOL was significantly impaired compared with age- and sex-matched US norms. At month 24, mean changes from baseline of SF-36 physical component score tended to be better for the rituximab group (+3.95 points, p=0.067) whereas mean changes from baseline of the SF-36 mental component score were significantly better for the azathioprine group (+4.23 points, p=0.041). CONCLUSIONS: Azathioprine-treated patients' for AAV maintenance therapy showed a decline in physical abilities when compared to RTX at M24 in the MAINRITSAN trial. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov/, NCT00748644
No file

Dates and versions

hal-01302407 , version 1 (14-04-2016)

Identifiers

  • HAL Id : hal-01302407 , version 1
  • PUBMED : 27049404

Cite

Gregory Pugnet, Christian Pagnoux, Benjamin Terrier, Elodie Perrodeau, Xavier Puéchal, et al.. Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. Clinical and experimental rheumatology, 2016, 34 (3), pp.S 54-59. ⟨hal-01302407⟩
353 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More